Investigational Gout Drugs Do Well in Clinical Trials
Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn't already responded well to be able to current treatment.
Ardea Biosciences had been the first to announce prosperous clinical trials of its experimental gout drug RDEA594, also referred to as Lesinurad. Lesinurad's mechanism of action is different from that of the commonly prescribed xanthine oxidase inhibitors gout medications (such as allopurinol and febuxostat), which decrease the development of uric acid.
Lesinurad is often a URAT1 transporter inhibitor which raises reduction of uric acid from the kidneys. Lesinurad is also active in opposition to another important regulator of urate secretion, OAT4. OAT4 is thought to be responsible for the high uric acid levels in gouty arthritis patients whose condition is caused or worsened by diuretics.
The Lesinurad study involved 208 gout patients who had high blood urate levels for at least Six months, even while taking the gout drug allopurinol. Sufferers continued on allopurinol and were randomly assigned to receive either a placebo or lesinurad at doses of 200 mg, 400 mg, or 600 mg for four weeks.
All three groups who were given lesinurad demonstrated substantially lower uric acid levels by the end of the month. The percentage of patients who achieved the target for uric acid levels after treatment was 28% in the placebo group, 71% in the 200 mg team, 76% in the 400 mg team, and 87% in the 600 mg group.
More lately, explains to you of BioCryst Pharmaceuticals rose 12% upon the release of the results of its phase 2b randomized, double-blind, study with the investigational gout drug BCX4208. BCX4208 is a novel enzyme inhibitor that acts upstream of xanthine oxidase in the purine metabolism pathway to reduce serum uric acid (sUA).
Its mechanism of action complements xanthine oxidase inhibitors for example allopurinol and febuxostat in reducing uric acid production, and BCX4208 is intended as an add-on therapy for those gouty arthritis patients who will not respond well to current gout medication.
Like Lesinurad, BCX4208 was studied in gouty arthritis patients who had experienced high blood urate levels for at least 6 months, despite taking the gout drug allopurinol. The 279 study participants were randomly assigned to take BCX4208 at doses of both 5 mg, 10 mg, 20 mg, or 40 mg once daily for 12 weeks. One group of patients was given a placebo. Just about all participants were also given allopurinal 300 mg once-daily.
- All but one of the doses showed that BCX4208 was superior to the placebo when used with allopurinol.
- The BCX4208 doses looked at in the study showed response rates ranging from 33% in order to 49%, compared to 18% for those taking the placebo.
At this point, Lesinurad appears the more promising of the two gout drugs, and the most likely to hit the market first. That outperformed BCX4208 in early clinical trials, and is farther ahead in the development and approval process. But individual responses to drugs vary, and gout patients will benefit from having two new approaches to relieving the symptoms of this painful condition.
Gout: Treatment, Causes, Massage Therapy, Prevention
Gout frequently affects the big toe in the foot. Massage therapy focused at the big toe nail helps in decreasing pain and swelling. Know its causes, symptoms, ...
Alex Ray Advocates for Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as a trusted online Canadian pharmacy from which to buy allopurinol and colchicine for gout. For more information about gout and gout medication, go to the online source www.colchicine.ca.